SYMBIOTEC (SYMBIOTEC)

News pulse:

Active threads

Symbiotec Pharmalab Q1 profit halves to ₹14.1 crore on new business costs

3 Min Read Symbiotec Pharmalab consolidated net profit fell by more than half in the June quarter, as costs from new businesses that are yet to generate revenue offset steady growth in its core active pharmaceutical ingredients (API) business. These are the company's first results since listing. Consolidated profit after tax stood at ₹14.1 crore in Q1 FY27, against ₹29.9 crore a year earlier.

breaking2 mentions75d ago

Symbiotec Pharmalab opens ₹1,757 crore IPO, bids due Aug 28

Symbiotec Pharmalab's ₹1,757 crore IPO opened for subscription on August 24, with a price band and key dates disclosed. Brokerages have issued positive views, citing the company's strong API portfolio growth, while grey market premiums are being tracked. The issue closes on August 28.

Intelligence feed

No articles in the last 24 hours.